CSI Market
Sign In | Register

Cellectar Biosciences Inc (CLRB) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access CLRB quarterly Cash Flow →
The data below summarizes Cellectar Biosciences Inc's cash flow activity from Dec 31 2021 to Dec 31 2025, enabling a period-by-period view of cash movement.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income-21.79
Depreciation & amortization0.21
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Goodwill, Impairment Loss0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets, Total0.00
Share-based Compensation2.26
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants-0.75
Increase Decrease In Fair Value Of Unhedged Derivative Instruments-
Reclassification Of Derivative Liabilities To Additional Paid In Capital-
Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net-
Non Cash Lease Expense-
Warrant Issuance Expense Operating Activities-
Depreciation And Amortization Of Assets0.08
Increase Decrease In Operating Lease Right Of Use Asset-
Increase Decrease In Operating Lease Liability-
Income taxes0.00
Losses/ -gains on Investments net0.00
Accounts Receivable0.00
Increase (Decrease) in Accounts Payable and Accrued Liabilities-3.16
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets0.12
Other Working Capital0.00
Other Noncash Expense0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-0.08
Discontinued operations0.00
Net Cash flow from Operating Activities-23.12
Investing Activities
Capital Expenditures-0.01
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Increase (Decrease) in Restricted Cash0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-0.01
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock7.24
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Reverse Stock Split Fractional Shares-
Proceeds From Deferred Issuance Costs-
Payments For Fractional Shares Reverse Stock Splits-
Payments Of Refunds From Deferred Issuance Costs-
Proceeds From Deferred Issuance Cost-
Finance Lease Principal Payments-
Proceeds From Issuance Of Common Stock And Preferred Stock Net Of Underwriting Issuance Costs-
Proceeds From Issuance Of Preferred Stock And Warrants Net Of Issuance Cost-
Proceeds From Warrant Exercises Net Of Costs-
Proceeds From Issuance Of Common Stock And Warrants Net5.79
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities13.03
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-23.12
Total Cash Flow-10.09
4 historic quarters locked

Sign in to unlock the full Cellectar Biosciences Inc cash flow history.

Sign In Create Free Account

About Cellectar Biosciences Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001104659-26-023167

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License